Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics is a promising biopharmaceutical company with a strong portfolio of precision medicines that target biologically validated drivers of cancers. Their lead program OKI-219 is showing promising preclinical results with further potential in solid tumors and vascular anomalies, with expected INDs in 1H27. Additionally, OnKure's unique approach of selectively targeting mutant PI3Kα with minimal effect on wild-type PI3Kα could lead to a more benign adverse event profile and potentially superior efficacy compared to competitors. With a healthy cash reserve and ongoing expansion efforts, OnKure is poised for long-term success and we reiterate our positive outlook on the stock.

Bears say

OnKure Therapeutics is a company with a promising drug development platform, but its current pipeline and business model present significant risks. The company's reliance on one segment for its clinical research and its limited revenue sources make it vulnerable to potential setbacks and market fluctuations. Additionally, the stock's current valuation seems inflated, as the company's NPV of $13.87 only rounds to $14, significantly lower than its current market price.

OKUR has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 2 analysts, OKUR has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.